SCHEMBL650607

SCHEMBL650607

Clc1cnc2[nH]cc(I)c2n1

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.62
CHEK1 O14757 1/20 0.42
JAK2 O60674 1/20 0.33
BRD4 O60885 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30259037 1.00 MAPK1 (0.62) MAPK1CHEK1JAK2BRD4
SCHEMBL31229864 0.85 MAPK1 (0.49) MAPK1CHEK1BRD4
SCHEMBL17005371 0.85 MAPK1 (0.49) MAPK1CHEK1BRD4
SCHEMBL12657766 0.84 MAPK1 (0.67) MAPK1CHEK1BRD4
SCHEMBL20846079 0.77 ALDH1A1 (0.41) MAPK1JAK2
SCHEMBL21821096 0.77 MAPK1 (0.62) MAPK1CHEK1BRD4
SCHEMBL30258999 0.77 MAPK1 (0.62) MAPK1CHEK1BRD4
SCHEMBL29488969 0.77 MAPK1 (1.00) MAPK1CHEK1JAK2BRD4
SCHEMBL649129 0.77 MAPK1 (1.00) MAPK1CHEK1JAK2BRD4
SCHEMBL14655319 0.72 JAK2 (0.40) JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108727369-B Influenza virus replication inhibitors and uses thereof 广东东阳光药业有限公司 2023-06-09 CN disclosed
EP-3555095-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
CN-110117285-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2023-02-03 CN disclosed
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-27 US disclosed
CN-106336413-B Compounds as JAK inhibitors and uses thereof 广东东阳光药业有限公司 2021-04-20 CN disclosed
CN-108218873-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2020-07-07 CN disclosed
US-20200085822-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-03-19 US disclosed
WO-2019057660-A1 INDOLE AND AZAINDOLE COMPOUNDS WITH SUBSTITUTED 6-MEMBERED ARYL AND HETEROARYL RINGS AS AGROCHEMICAL FUNGICIDES BASF SE (DE) 2019-03-28 WO disclosed
WO-2019057660-A1 INDOLE AND AZAINDOLE COMPOUNDS WITH SUBSTITUTED 6-MEMBERED ARYL AND HETEROARYL RINGS AS AGROCHEMICAL FUNGICIDES BASF SE (DE) 2019-03-28 WO disclosed
EP-2858984-A1 INHIBITORS OF INFLUENZA VIRUSES REPLICATION Vertex Pharmaceuticals Inc. (US) 2015-04-15 EP disclosed
WO-2009106444-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 WO disclosed
WO-2009106444-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 WO disclosed
WO-2009106441-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 WO disclosed
US-20090215785-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 US disclosed
US-20090215785-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 US disclosed
US-20090215785-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2009-08-27 US disclosed
CN-101098872-A Pyrrolopyrazines and pyrazolopyrazines useful as protein kinase inhibitors VERTEX PHARMA (US) 2008-01-02 CN disclosed
EP-1814882-A1 PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2007-08-08 EP disclosed
US-20060258662-A1 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2006-11-16 US disclosed
WO-2006058074-A1 PYRROLOPYRAZINES AND PYRAZOLOPYRAZINES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof ZC3HAV1, MAVS, POLRMT MAPK1 2020/4885CHEK1 1527/4885JAK2 1611/4885
US-20090215785-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, JAK2 MAPK1 431/4885CHEK1 1676/4885JAK2 3/4885
US-20060258662-A1 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases AURKC, AURKA, PLK1 MAPK1 390/4885CHEK1 103/4885JAK2 278/4885
US-20200085822-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF ZC3HAV1, MAVS, POLRMT MAPK1 2020/4885CHEK1 1527/4885JAK2 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.